Hidradenitis suppurativa treatment experiences vary widely among patients; a new study highlights the need for personalised care and shared decision-making.

Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.

Detailed price information for Collegium Pharma (COLL-Q) from The Globe and Mail including charting and trades.

Study authors examined the relationship between the use of combined oral contraceptives and the onset of hidradenitis suppurativa.

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Benzoyl peroxide is one of the most effective and commonly used acne treatments. You’ll find it in prescription and ...

However, for the Company, 2024 was both a “year of restructuring” amidst challenges and a “year of breakthroughs” with emerging potentials. Although the overall performance is experiencing short-term ...

Steven Daniel Daveluy, MD, FAAD, discussed how artificial intelligence (AI) can leverage extensive patient data and guide dermatologists to improve early diagnosis and treatment of rare dermatological ...

Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome ...

Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 ...

The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted ...